Aktuelle Medikamentenstudien

GigIANT

A randomized, parallel-group, double-blind, placebo-controlled, multicenter trial to investigate the efficacy and safety of subcutaneously administered secukinumab in patients with new-onset of giant call arthritis who are in clinical remission and eligible for treatment with glucocoerticoid-monotherapy (GigIANT)

EudraCT Number: 2021-002622-24, aktiv

FASTLANE

Tofacitinib in Early Active Axial Spondyloarthritis. A prospective Randomized, Double-Blind, Placebo-Controlled Multicentre Study FASLANE

EU-CT Number 2023-505050-18-00, aktiv

Safeguard

A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenance of response in participants with non-radiographic axial spondyloarthritis who achieved remission (Safeguard)

EudraCT Number: 2022-001153-23, aktiv

RUBY

A multinational, prospective, non-interventional study, to assess real world use of a tozilizumab biosimilar in rheumatoid arthritis patients (RUBY)

aktiv

PA0016

Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of bimekizumab in subjects with active nonradiographic axial spondyloarthritis (PA0016).

EudraCT Number: 2017-003064-13, geplant

SPECIFI-RA

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety study of SAR441566 plus Methotrexate in Adults with Moderate-to-Severe Rheumatoid Arthritis, SPECIFI-RA

EU trial number 2023-503910-60, aktiv

LATITUDE-PsA-3001

A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Who Are Naïve to Biologic Disease Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)

geplant

A Phase 2, Randomized, Doube-Blind, Placebo-Controlled Study to Evaluate the Effficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis

geplant

A Phase 3, parallel-group, randomized, double-blind, 3-arm, placebo-controlled, multicenter study to investigate the efficacy and safety of subcutaneous sonelokimab in male and female participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs

geplant

A Phase 3, parallel-group, randomized, double-blind, 4-arm, placebo-controlled, multicenter study with risankizumab as active reference arm, to investigate the efficacy and safety of subcutaneous sonelokimab in male and female participants aged 18 years and over with active psoriatic arthritis and previous inadequate response or intolerance to tumor necrosis factor-α inhibitor

geplant

GUS-PsA-Early

Real-world study of guselkumab in PsA patients with short disease duration and oligoarthritis (GUS-PsA-Early)

geplant